Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Research & Development (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Research & Development for 6 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 7.83% year-over-year to $9.0 million, compared with a TTM value of $36.5 million through Dec 2025, down 7.45%, and an annual FY2025 reading of $36.5 million, down 7.45% over the prior year.
  • Research & Development was $9.0 million for Q4 2025 at Cytek Biosciences, roughly flat from $9.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.1 million in Q2 2023 and bottomed at $5.1 million in Q1 2021.
  • Average Research & Development over 5 years is $9.0 million, with a median of $9.3 million recorded in 2024.
  • The sharpest move saw Research & Development skyrocketed 112.41% in 2021, then fell 17.59% in 2024.
  • Year by year, Research & Development stood at $7.1 million in 2021, then surged by 37.75% to $9.7 million in 2022, then rose by 11.51% to $10.9 million in 2023, then decreased by 10.54% to $9.7 million in 2024, then fell by 7.83% to $9.0 million in 2025.
  • Business Quant data shows Research & Development for CTKB at $9.0 million in Q4 2025, $9.0 million in Q3 2025, and $8.8 million in Q2 2025.